Connect Biopharma Expects To Report Topline Data From Phase 1b Intravenous Administration Study In Q1 And Seabreeze STAT Studies In Acute Asthma And COPD Midyear
Benzinga Newsdesk 10 months ago
News
– Announced new data demonstrating a unique mechanism of action supporting the best-in-class potential of rademikibart –– Recruitment ongoing for Phase 1b study of intravenously-administered rademikibart designed to
– Announced new data demonstrating a unique mechanism of action supporting the best-in-class potential of rademikibart –
– Recruitment ongoing for Phase 1b study of intravenously-administered rademikibart designed to further confirm its unique ability to rapidly improve airway function with topline results expected in first quarter 2026 –
– Recruitment ongoing for Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD; expect to report topline data from both studies in mid-2026 –
– Strong balance sheet with cash runway into 2027 through key clinical catalysts –
SAN DIEGO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today highlighted new mechanism of action data for rademikibart and outlined its priorities for 2026.